|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J06BB16
|
|
gptkbp:brand
|
gptkb:Synagis
|
|
gptkbp:CASNumber
|
gptkb:188039-54-5
|
|
gptkbp:cost
|
expensive
|
|
gptkbp:developedBy
|
gptkb:MedImmune
|
|
gptkbp:halfLife
|
20 days
|
|
gptkbp:hasMolecularFormula
|
C6418H9910N1694O1987S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
palivizumab
|
|
gptkbp:indication
|
high-risk infants
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to RSV F protein and inhibits viral entry
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:product
|
IgG1 kappa monoclonal antibody
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
injection site reaction
rash
|
|
gptkbp:target
|
gptkb:RSV_F_protein
|
|
gptkbp:UNII
|
P0MUJ6XSE6
|
|
gptkbp:usedFor
|
prevention of respiratory syncytial virus infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:respiratory_syncytial_virus
gptkb:Human_respiratory_syncytial_virus
gptkb:RSV
|
|
gptkbp:bfsLayer
|
6
|